Niki BioSolutions, Inc.
NIKI · XNASCIK 1734005fmd_1QC4QJC8QPCAZMRK95ZZCTNX5SManufacturing · Measuring & Controlling Devices, NECTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 17 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (0)
- Net income
- (1)
Latest quarter · Q4 FY2025
Millions- Net income
- (0)
Daily close · NIKIIEX trades only
Nov 10, 2026 to Nov 10, 2026 · 1 sessions1.67 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
Niki BioSolutions, Inc. (NIKI) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Net income | -$1.4 million | -$4.3 million | 20-F 2026-03-27 · proof | |
| Cash from operating activities | -$1.8 million | -$1.2 million | 20-F 2026-03-27 · proof | |
| Total assets | $18.7 million | $16.1 million | +15.9% | 20-F 2026-03-27 · proof |
| Total liabilities | $4.9 million | $4.4 million | +12.6% | 20-F 2026-03-27 · proof |
| Cash and cash equivalents | $3.5 million | $874,238 | +295% | 20-F 2026-03-27 · proof |
- What was Niki BioSolutions, Inc. (NIKI)'s net income in fiscal 2025?
- Niki BioSolutions, Inc. (NIKI) reported net income of -$1.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$4.3 million the year before. Source: the 20-F filed with the SEC on Mar 27, 2026. SEC
- What was Niki BioSolutions, Inc. (NIKI)'s cash from operating activities in fiscal 2025?
- Niki BioSolutions, Inc. (NIKI) reported cash from operating activities of -$1.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$1.2 million the year before. Source: the 20-F filed with the SEC on Mar 27, 2026. SEC
- What are Niki BioSolutions, Inc. (NIKI)'s total assets?
- As of Dec 31, 2025, Niki BioSolutions, Inc. (NIKI) reported total assets of $18.7 million, against $16.1 million a year earlier (+15.9%). Source: the 20-F filed with the SEC on Mar 27, 2026. SEC
- What are Niki BioSolutions, Inc. (NIKI)'s total liabilities?
- As of Dec 31, 2025, Niki BioSolutions, Inc. (NIKI) reported total liabilities of $4.9 million, against $4.4 million a year earlier (+12.6%). Source: the 20-F filed with the SEC on Mar 27, 2026. SEC
- What are Niki BioSolutions, Inc. (NIKI)'s cash and cash equivalents?
- As of Dec 31, 2025, Niki BioSolutions, Inc. (NIKI) reported cash and cash equivalents of $3.5 million, against $874,238 a year earlier (+295%). Source: the 20-F filed with the SEC on Mar 27, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:NIKI&period_type=annual&limit=5"Information only, not investment advice.